Chemo-Induced Myelosuppression Presentation and Management in ES-SCLCByKennon McCollum, DNPNovember 22nd 2025
What Biomarker Testing Is Required Up Front in Ovarian Cancer?ByCourtney R. Arn, APRN-CNPNovember 18th 2025
FDA Approves Epcoritamab Plus Lenalidomide/Rituximab in R/R Follicular LymphomaByBridget HoytNovember 18th 2025
Linking Mechanism of Action to Safety Profiles in mCRC TreatmentByGabriel Schwartz, MSN, NPNovember 15th 2025